These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34186055)

  • 1. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
    Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
    Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
    Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
    Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
    Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
    Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
    Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
    Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
    Samal S; Patnaik A; Sahu F; Purkait S
    Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
    Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
    J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis.
    Lu VM; Luther EM; Eichberg DG; Morell AA; Shah AH; Komotar RJ; Ivan ME
    World Neurosurg; 2022 Jul; 163():87-95.e1. PubMed ID: 35439620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of H3K27me3 in WHO grade 3 meningioma.
    Maier AD; Brøchner CB; Mirian C; Haslund-Vinding J; Bartek J; Ekström TJ; Poulsen FR; Scheie D; Mathiesen T
    Brain Tumor Pathol; 2022 Oct; 39(4):200-209. PubMed ID: 35678886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of H3K27me3 in meningiomas.
    Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
    Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.
    Gauchotte G; Peyre M; Pouget C; Cazals-Hatem D; Polivka M; Rech F; Varlet P; Loiseau H; Lacomme S; Mokhtari K; Kalamarides M; Bielle F
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):754-762. PubMed ID: 32447376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.
    Ehret F; Perez E; Teichmann D; Meier S; Geiler C; Zeus C; Franke H; Roohani S; Wasilewski D; Onken J; Vajkoczy P; Schweizer L; Kaul D; Capper D
    Acta Neuropathol Commun; 2024 May; 12(1):74. PubMed ID: 38720399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.
    Bertero L; Dalla Dea G; Osella-Abate S; Botta C; Castellano I; Morra I; Pollo B; Calatozzolo C; Patriarca S; Mantovani C; Rudà R; Tardivo V; Zenga F; Garbossa D; Papotti M; Soffietti R; Ricardi U; Cassoni P
    J Neuropathol Exp Neurol; 2019 Mar; 78(3):248-256. PubMed ID: 30689922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.
    Chen WC; Vasudevan HN; Choudhury A; Pekmezci M; Lucas CG; Phillips J; Magill ST; Susko MS; Braunstein SE; Oberheim Bush NA; Boreta L; Nakamura JL; Villanueva-Meyer JE; Sneed PK; Perry A; McDermott MW; Solomon DA; Theodosopoulos PV; Raleigh DR
    Neurosurgery; 2020 Dec; 88(1):202-210. PubMed ID: 32860417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
    San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
    Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.